Approximately one-third of patients with relapsed or refractory mantle cell lymphoma (MCL) in this study treated with CAR T-cell therapy experienced disease progression, with a median progression time ...
The findings show most patients with low-risk myelodysplastic syndrome (MDS) will die before progression. A new analysis of nearly 2000 patients with low-risk myelodysplastic syndrome (MDS) has ...
Please provide your email address to receive an email when new articles are posted on . Disease progression occurred in more patients receiving placebo vs. an oral lysophosphatidic acid receptor 1 ...
Patients with EGFR-mutated non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib (Tagrisso) had better progression-free survival (PFS) in second line when they continued ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results